AbbVie pours $223M into building out its biologics capacity in Singapore
AbbVie is not only building out its pipeline, but also its manufacturing footprint. The Chicago-based pharma is spending $223 million to extend its only manufacturing site in Asia and boost its biologics production.
The facility in Singapore, which can already produce biologics and small molecules, is envisioned to add at least 100 jobs to a total of around 500 workers once it’s fully operational. The extension will boost its biologics drug substance capabilities by 24,000 liters.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.